









Markets
/
Stocks
/
nasdaq-mrkr
/

Marker Therapeutics Inc

MRKR

1.010USD

-0.040-3.81%

Close 10/10, 16:00（ET）Quotes delayed by 15 min

11.41MMarket Cap

LossP/E TTM



Marker Therapeutics Inc

1.010

-0.040-3.81%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Marker Therapeutics Inc

Currency: USD Updated: 2025-10-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Marker Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

91 / 502

Overall Ranking

184 / 4697

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

8.167

Target Price

+677.78%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Marker Therapeutics Inc Highlights

StrengthsRisks

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumors associated antigens (TAAs), which are tumor targets, and kill tumor cells expressing those targets. It is developing two product candidates, which include Autologous multiTAA product for the treatment of lymphoma and pancreatic cancer (MT-601) and Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601, a multiTAA-specific autologous T cell product capable of recognizing multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 87.59% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 6.59M.

Overvalued

The company’s latest PE is -0.75, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.41M shares, decreasing 19.82% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 69.44K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 6.29.

Financial Health

Currency: USD Updated: 2025-10-10

The company's current financial score is 8.05, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 861.18K, representing a year-over-year decrease of 26.35%, while its net profit experienced a year-over-year decrease of 83.14%.

Score

Industry at a Glance

Previous score

8.05

Change



Financials

9.84

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.05

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.13

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Marker Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-10

The company’s current valuation score is 8.40, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.75, which is -70.86% below the recent high of -0.22 and -1048.81% above the recent low of -8.56.

Score

Industry at a Glance

Previous score

8.40

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 91/502

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-10

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Marker Therapeutics Inc is 8.00, with a high of 12.50 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

8.167

Target Price

+708.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Marker Therapeutics Inc

MRKR

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-10

The company’s current price momentum score is 6.82, which is lower than the Biotechnology & Medical Research industry's average of 6.83. Sideways: Currently, the stock price is trading between the resistance level at 1.14 and the support level at 0.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.99

Change

-0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.050

Neutral

RSI(14)

51.346

Neutral

STOCH(KDJ)(9,3,3)

66.152

Neutral

ATR(14)

0.075

High Vlolatility

CCI(14)

74.056

Neutral

Williams %R

42.857

Buy

TRIX(12,20)

0.054

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.056

Sell

MA10

0.987

Buy

MA20

0.959

Buy

MA50

1.040

Sell

MA100

1.276

Sell

MA200

1.483

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-10

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 26.37%, representing a quarter-over-quarter decrease of 41.20%. The largest institutional shareholder is The Vanguard, holding a total of 275.35K shares, representing 2.13% of shares outstanding, with 6.28% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

New Enterprise Associates (NEA)

1.63M

Wilson (John Robert)

641.80K

-17.84%

Blue Owl Capital Holdings LP

554.25K

Aisling Capital Management LP

325.37K

+3.53%

The Vanguard Group, Inc.

Star Investors

275.35K

Vera (Juan F. M.D.)

267.18K

Alyeska Investment Group, L.P.

213.02K

-18.63%

Geode Capital Management, L.L.C.

95.77K

+8.01%

LPL Financial LLC

73.75K

+0.71%

Renaissance Technologies LLC

Star Investors

69.44K

-16.85%

Risk Assessment

Currency: USD Updated: 2025-10-10

The company’s current risk assessment score is 1.60, which is lower than the Biotechnology & Medical Research industry's average of 3.48. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.